Abstract: Objective: Previous studies have been found that the dysregulation of Ras association domain protein 10 (RASSF10) was involved in human malignances tightly, whereas the expression of RASSF10 in colorectal cancer remains unclear. This study aims to investigate the relationship between the expressions of RASSF10 and clinical significance in colorectal cancer. Methods: Applying immunohistochemistry to analyze the RASSF10 expressions in 102 colorectal cancer tissues and adjacent normal tissues. The association of RASSF10 expressions with the patients’ clinical features was investigated, as well as the relativity between RASSF10 expression and the prognosis of colorectal cancer patients. Results: RASSF10 was down-regulated in colorectal cancer tissues with a high expression rate of 30.39% (RASSF10 of 31 patients were overexpressed in total 102 patients). The expression of RASSF10 in colorectal cancer tissues was significantly lower than that in normal tissues (P<0.05). The significant associations between the expressions of RASSF10 lymph node metastasis and TNM stage were observed．The expression of RASSF10 was irrelevance with patient’s age, gender, differentiation and tumor invasive depth and tumor location (P>0.05). Prognosis of patients with RASSF10 low expression was significantly shorter compared with that of patients with RASSF10 high expression( P= 0.0032). Conclusion: RASSF10 was down-regulated in colorectal cancer and involved in the tumorigenesis and development of colorectal cancer. RASSF10 might be a new biomarker and therapy target of colorectal cancer.